Assessing the economics of biologic and small molecule therapies for the treatment of moderate to severe ulcerative colitis in Japan: a cost per responder analysis of upadacitinib.
Masayuki SarutaIsao KawaguchiYuji OgawaYuri Sanchez GonzalezNaoki NumajiriXiaohe TangRussell MillerPublished in: Journal of medical economics (2024)
The results of this cost per responder analysis suggest upadacitinib is a cost-effective option for the first- and second-line treatment of moderately to severely active ulcerative colitis in Japan.